Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes: 德谷胰岛素/门冬胰岛素与双相门冬胰岛素30相比在维持治疗期间低血糖的发生率更低:两项在2型糖尿病中进行的3a期研究联合分析
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the basal analog insulin degludec and the rapid‐acting prandial insulin aspart in a single injection. The present combined analysis of two Phase 3a trials compared the incidence of hypoglycemia in participants treated twice daily with IDegAsp or biphasic insulin aspart 30 (BIAsp 30). Methods: Hypoglycemia data were analyzed from two similarly designed randomized controlled open‐label treat‐to‐target Phase 3a clinical trials of adults with type 2 diabetes (T2D). Participants were treated twice daily with IDegAsp or BIAsp 30, with breakfast and their main evening meal. Results: Over 26 weeks, the rates of overall confirmed, nocturnal confirmed and severe hypoglycemic events were 19%, 57%, and 39% lower, respectively, with IDegAsp (n = 504) than BIAsp 30 (n = 364); estimated rate ratios were 0.81 (95% confidence interval [CI] 0.67, 0.98; P = 0.0341), 0.43 (95% CI 0.31, 0.59; P = 0.0001), and 0.61 (95% CI 0.26, 1.45; P = NS). The between‐treatment differences were more pronounced during the maintenance period (≥16 weeks); compared with BIAsp 30, rates of overall confirmed, nocturnal confirmed and severe hypoglycemic events with IDegAsp were 0.69 (95% CI 0.55, 0.87; −31%; P = 0.0015); 0.38 (95% CI 0.25, 0.58; −62%; P < 0.0001), and 0.16 (95% CI 0.04, 0.59; −84%; P = 0.0061), respectively. Conclusions: Compared with BIAsp 30 twice daily, IDegAsp twice daily provided similar improvements in glycemic control with a lower risk of hypoglycemia, particularly nocturnal hypoglycemia, in subjects with T2D previously treated with insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“As the disease progresses, many people require further intensification of their treatment(1) by either the sequential addition of bolus insulin to basal regimens, the transition to injections of premixed insulin,(2) or the addition of a glucagon-like peptide-1 receptor agonist.(2) Adding bolus insulin as a separate in…”
BackgroundThree-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Chow, E., Bernjak, A., Williams, S., Fawdry, R. A., Hibbert, S., Freeman, J., Sheridan, P. J., & Heller, S. R. (2014) · Diabetes · doi:10.2337/db13-0468 · Cited by 403
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397
Self-citationRatner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346 · cited 2×
“Previously, a prespecified meta-analysis of hypoglycemia rates demonstrated that improvements in HbA1c^ can be achieved with fewer hypoglycemic episodes, particularly nocturnal episodes, with IDeg versus IGlar across a broad spectrum of people with diabetes.(5) To extend the findings of that meta-analysis, a combined…”
BackgroundMethodThe impact of non-severe hypoglycemic events on work productivity and diabetes management
Brod, M., Christensen, T., Thomsen, T. L., & Bushnell, D. M. (2011) · Value in Health · doi:10.1016/j.jval.2011.02.001 · Cited by 284
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226 · cited 1×
“maintained and clearly separated from the flat basal glucose-lowering effects in participants with T1D, indicating that no stacking should be observed with IDegAsp when dosed twice daily.(10)”
Background
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
EADSG Guidelines: Insulin Therapy in Diabetes
Silver, B., Ramaiya, K., Andrew, S. B., Fredrick, O., Bajaj, S., Kalra, S., Charlotte, B. M., Claudine, K., & Makhoba, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0384-6 · Cited by 179
“Furthermore, a recent systematic review suggests that in insulin-treated T2DM, insulin degludec/insulin aspart 70/30 twice daily is comparable to biphasic insulin aspart 30 twice daily and imposes a lower risk of nocturnal hypoglycemia [101].”
Background
Metadata
- Authors
- Christiansen, J. S., Niskanen, L., Rasmussen, S., Johansen, T., & Fulcher, G.
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2016-03-06
- Volume
- 8
- Issue
- 5
- Pages
- 720-728
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W2298808807
- Cited by
- 26
- References
- 8
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes: 德谷胰岛素/门冬胰岛素与双相门冬胰岛素30相比在维持治疗期间低血糖的发生率更低:两项在2型糖尿病中进行的3a期研究联合分析. https://app.cochat.ai/papers/10.1111/1753-0407.12355
- The paper
- Christiansen, J. S., Niskanen, L., Rasmussen, S., Johansen, T., & Fulcher, G. (2016). Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes: 德谷胰岛素/门冬胰岛素与双相门冬胰岛素30相比在维持治疗期间低血糖的发生率更低:两项在2型糖尿病中进行的3a期研究联合分析. Journal of Diabetes. https://doi.org/10.1111/1753-0407.12355
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.